Bio-Gene Technology

Bio-Gene Technology Enterprise Value

The Enterprise Value (EV) of Bio-Gene Technology (BGT.AX) as of Oct 22, 2026 is 7.52 M AUD. In the previous year, Enterprise Value (EV) was 8.37 M AUD — a change of -10.19% (lower).

Enterprise Value

7.52 MAUD

YoY

-10.19%

Last updated:

Enterprise Value (EV) of Bio-Gene Technology is 2026 7.52 M AUD. Enterprise Value (EV) of Bio-Gene Technology was 2025 8.37 M AUD. It decreases by -10.19% lower compared to the previous year.

The Bio-Gene Technology Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
5.11 M AUD
Jan 1, 2020
4.10 M AUD
Jan 1, 2021
5.67 M AUD
Jan 1, 2022
3.12 M AUD
Jan 1, 2023
6.47 M AUD
Jan 1, 2024
7.25 M AUD
Jan 1, 2025
8.37 M AUD
Jan 1, 2026
7.52 M AUD
The Bio-Gene Technology Enterprise Value history
YEAREnterprise ValueYoY
7.52 MAUD-10.19%
8.37 MAUD+15.49%
7.25 MAUD+12.08%
6.47 MAUD+107.59%
3.12 MAUD-45.10%
5.67 MAUD+38.49%
4.10 MAUD-19.79%
5.11 MAUD+76.10%
2.90 MAUD+256.30%
814,015.00AUD-91.30%
9.36 MAUD+1.16%
9.25 MAUD-1.68%
9.41 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology Ltd develops and commercializes insecticides using beta-triketone platform technology. The company's lead products are Flavocide, a chemically synthesized insecticide based on flavesone, and Qcide, a natural oil product containing tasmanone extracted from Gympie Messmate leaves via steam distillation. These products address insecticide resistance and toxicity issues in crop protection, storage, public health, animal health, and consumer applications. Insecticide manufacturers purchase the company's platform technology and products for commercialization across multiple sectors. The firm's beta-triketone platform provides multiple solutions for insecticide manufacturers seeking to develop novel pest control products. Flavocide and Qcide represent the company's primary commercial offerings, with Flavocide targeting synthetic insecticide markets and Qcide focusing on natural oil-based solutions. The company's technology enables the development of targeted insect control solutions for various applications including agricultural crop protection and public health management. Bio-Gene Technology Ltd. aims to develop a portfolio of targeted insect control solutions for insecticide manufacturers. The company's platform technology allows manufacturers to create new products addressing resistance and toxicity challenges. Through its two lead products, the company provides both synthetic and natural options for the insecticide market, targeting manufacturers who seek innovative solutions for pest management across different industry segments. Bio-Gene Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Gene Technology stock

Enterprise Value (EV) of Bio-Gene Technology is 7.52 M AUD in 2026.

Enterprise Value (EV) of Bio-Gene Technology changed from 8.37 M AUD to 7.52 M AUD, representing a -10.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s AUD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' AUD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Bio-Gene Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bio-Gene Technology

All Key Metrics — Bio-Gene Technology